Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of atogepant for migraine prevention
NL-OMON54251Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine and chronic migraine, sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with at least 1 treatment-emergent adverse event. Started Feb 2022; status: recruiting.
02
Drugs
atogepant
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on NL-OMON54251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54251.